Rystiggo (ripretinib) is a kinase inhibitor approved for the treatment of advanced gastrointestinal stromal tumors (GIST) that have progressed on or after treatment with other kinase inhibitors [1]. While Rystiggo is not a cancer treatment itself, it targets specific kinases involved in tumor growth pathways, making it effective against certain cancers like GIST [1][2].
How does Rystiggo work against GIST?
Rystigget targets KIT and PDGFRA kinases, which are often mutated and drive the growth of GIST [1][3]. By inhibiting these mutated kinases, Rystiggo can slow or stop the growth of GIST cells [2]. It is designed to be effective against specific mutations, including the KIT exon 11 and exon 17/18 mutations, and PDGFRA exon 18 mutations [1].
What stage of GIST is Rystiggo used for?
Rystiggo is indicated for patients with advanced GIST whose disease has progressed despite prior treatment with other kinase inhibitors [1]. This means it is typically used in later lines of therapy for GIST management [1][4].
What are the potential side effects of Rystiggo?
Common side effects reported with Rystiggo include hair color changes, fatigue, nausea, abdominal pain, diarrhea, decreased appetite, and rash [1]. More serious side effects can include hypertension, cardiac dysfunction, and skin reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How long does Rystiggo treatment typically last?
The duration of Rystiggo treatment depends on individual patient response and tolerability. Treatment continues as long as it is effective and the patient can tolerate the side effects [1].
Who manufactures Rystiggo?
Rystiggo is manufactured by Deciphera Pharmaceuticals [5].
What is the patent status of Rystiggo?
Drug patents for Rystiggo are listed on DrugPatentWatch.com, which tracks patent information for pharmaceuticals [6]. Information on specific patent expiry dates and any challenges to these patents can be found through resources like DrugPatentWatch [6].
Are there alternatives to Rystiggo for advanced GIST?
Before Rystiggo, other kinase inhibitors such as imatinib, sunitinib, and regorafenib were used for advanced GIST [4]. The choice of treatment depends on the specific mutations present in the GIST, previous treatments received, and the patient's overall health [4].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216524s000lbl.pdf
2. https://www.drugpatentwatch.com/drug/1673860/rystiggo
3. https://www.nejm.org/doi/full/10.1056/NEJMoa2205501
4. https://www.cancer.net/cancer-types/gastrointestinal-stromal-tumor-gist/treatment
5. https://www.decipherapharmaceuticals.com/pipeline/
6. https://www.drugpatentwatch.com/